

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Biostatistics](#) [Breast Cancer](#) [Cancer Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)


[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)



Office Phone

646-227-3395

Email

beggc@mskcc.org

Education

University of Glasgow, UK

Current Research Interests

Dr. Begg has long-standing interests in cancer epidemiology, health services research, clinical trials, genetics and genomics, and the statistical methods that support scientific studies in these disciplines. He has collaborated closely with countless departmental colleagues over the years, most recently with Marinela Capanu, Angela Green, Audrey Mauguen, Irene Orlow, Irina Ostrovnaya, Venkatraman Seshan, Ronglai Shen, Allison Lipitz-Snyderman, Axel Martin and post-doctoral fellows Saptarshi Chakraborty and Zoe Guan. He serves as a scientific advisor to numerous other cancer centers and extra-mural research groups. He is a joint principal investigator of the NCI-funded international GEM study that addresses the genetic and environmental risks of melanoma and of an NCI R25 training grant. Dr. Begg also currently serves as Editor-in-Chief of the international scholarly journal *Clinical Trials*, the journal of the Society for Clinical Trials.

Publications

Selected peer-reviewed publications:

Ostrovnaya I, Mauguen A, Seshan VE, Begg CB. Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. *Biometrics*. 2021 Mar;77(1):283-292. doi: 10.1111/biom.13256. Epub 2020 Apr 2. PMID: 32135575; PMCID: PMC8514156.

Chakraborty S, Martin A, Guan Z, Begg CB, Shen R. Mining mutation contexts across the cancer genome to map tumor site of origin. *Nat Commun*. 2021 May 24;12(1):3051. doi: 10.1038/s41467-021-23094-z. PMID: 34031376; PMCID: PMC8144407.

Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS. Contralateral breast cancers: Independent cancers or metastases? *Int J Cancer*. 2018 Jan 15;142(2):347-356. doi: 10.1002/ijc.31051. Epub 2017 Sep 28. PMID: 28921573; PMCID: PMC5749409.

Mauguen A, Begg CB. Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity. *Epidemiology*. 2016 Jul;27(4):531-7. doi: 10.1097/EDE.0000000000000499. PMID: 27096256; PMCID: PMC5495014.

Begg CB. A strategy for distinguishing optimal cancer subtypes. *Int J Cancer*. 2011 Aug 15;129(4):931-7. doi: 10.1002/ijc.25714. Epub 2010 Nov 18. PMID: 20949563; PMCID: PMC3043163.

[Visit PubMed for a full listing of Colin Begg's journal articles.](#)

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

My Downloads

[Clonality Testing: Excel Macros](#)

[Clonality Testing: R Package](#)

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Colin Begg discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

PREVIOUS

[Ray Baser](#)

NEXT

[Ayyüce Begüm Bektaş](#)

Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center